The new GATA antibody
A recently conducted study has shown that TRPS1 is expressed very highly in triple-negative breast cancer (TNBC). Expression was significantly higher than the GATA3 expression in metaplastic (85% vs. 21%) and non-metaplastic (86% vs. 51%) TNBC. Accordingly, TRPS1 has proven to be a highly specific and sensitive marker for all types of breast cancer, in particular TNBC. (Di Ai et al.; "TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol 34: 710-719, 2021)
Products
| Product | Manufacturer | Clone | Amount | Status | Order no. | Info | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ZR382 | 1 ml | Concentrate | CE/IVD | Z2673RL | |||||||||||||||||||||
|
ZR382 | 0.5 ml | Concentrate | CE/IVD | Z2673RS | |||||||||||||||||||||
|
ZR382 | 0.1 ml | Concentrate | CE/IVD | Z2673RT | |||||||||||||||||||||
|
ZR382 | 7 ml | r-t-u | CE/IVD | Z2673RP |
Further topics
Movember 2024
News about the IVDR
The IVDR, in force since May 26, 2022, represents a turning point in the EU-wide harmonization of patient safety. At the same time, it places high demands on us as manufacturers and on you as a user of in vitro diagnostic medical devices to implement the new regulation. We would like to meet this challenge together with you for the benefit of your patients. It is important to us to certify our portfolio of diagnostic solutions in compliance with the IVDR in due time. Therefore, we would like to keep you informed about our progress with the implementation of the IVDR.
